Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
- DOI
- 10.1177/1756286420987941
- Published
- 2021
- Container
- Therapeutic advances in neurological disorders
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/1756286420987941,
title = {Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.},
author = {Kappos L and Cohan S and Arnold DL and Robinson RR and Holman J and Fam S and Parks B and Xiao S and Castro-Borrero W},
year = {2021},
journal = {Therapeutic advances in neurological disorders},
doi = {10.1177/1756286420987941},
url = {https://doi.org/10.1177/1756286420987941}
}RIS
TY - JOUR TI - Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination. AU - Kappos L AU - Cohan S AU - Arnold DL AU - Robinson RR AU - Holman J AU - Fam S AU - Parks B AU - Xiao S AU - Castro-Borrero W PY - 2021 JO - Therapeutic advances in neurological disorders DO - 10.1177/1756286420987941 UR - https://doi.org/10.1177/1756286420987941 ER -
APA
L, K., S, C., DL, A., RR, R., J, H., S, F., B, P., S, X., & W, C. (2021). Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.. Therapeutic advances in neurological disorders. https://doi.org/10.1177/1756286420987941
Source records
- pubmed · retrieved 2026-09-25T18:46:53.530Z